Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it?

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while AstraZeneca leads on invention.

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even in times of uncertainty. He pointed out that earnings are once again playing a significant role in driving market behavior.

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Qatar pushes back on reports of $400M Boeing jet gift to Trump

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation and workforce development.

People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.